Topping Today's Watchlist: (Nasdaq: IMNN) Grabs Our Focus With 7 Key Potential Catalysts

On Wednesday morning, an under-the-radar company

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Topping Today's Watchlist: (Nasdaq: IMNN) Grabs Our Focus With 7 Key Potential Catalysts *Click Here To Get Our Alerts Faster Via SMS* September 10th Greetings Readers, On Wednesday morning, an under-the-radar company sent out a speaker list that would not look out of place at a major oncology congress. The release, dated September 9th, 2026, laid out the full agenda for IMUNON, Inc. (Nasdaq: IMNN)'s R&D Day on September 23rd at the Sofitel New York in NYC. On the program: Amir Jazaeri, M.D., of UT MD Anderson Cancer Center, and Premal H. Thaker, M.D., of Washington University, alongside Chief Executive Officer Stacy R. Lindborg, Ph.D., and Chief Medical Officer Douglas V. Faller, M.D., Ph.D. If you’d like to join the event, you can register for the webcast by clicking here. What earned that room is a set of figures reported earlier this year. In its Phase 2 OVATION 2 study in newly diagnosed advanced ovarian cancer, patients who received IMNN-001 alongside standard neoadjuvant and adjuvant chemotherapy showed median overall survival of 45.1 months against 30.4 months for chemotherapy alone, a difference of 14.7 months. In the group that also received PARP inhibitor maintenance, the reported gap widened to 24.2 months, or 65.6 against 41.4, according to the company's July 21st, 2026 release. IMNN is a clinical-stage biopharmaceutical company with a singular focus: deploying a first-in-class DNA-based immunotherapy to confront one of oncology's most treatment-resistant cancers. The company's technology does not follow the usual path of layering another chemotherapy on top of an already-stressed treatment framework. Instead, it introduces a fundamentally different biological approach designed to activate the patient's own immune system against the tumor. The core of that approach is the TheraPlas® nanoparticle platform, a proprietary gene delivery system that carries therapeutic DNA directly to the tumor site without using a viral vector. The lead program, IMNN-001, uses this platform to express interleukin-12 (IL-12), a potent immune-activating cytokine, directly in the abdominal cavity where ovarian tumors typically spread. Earlier IL-12 therapies failed because systemic administration caused severe toxicities. IMNN-001 addresses that problem with localized delivery and a safety profile that Phase 2 data supports. The OVATION 2 data was subsequently published in the peer-reviewed journal Gynecologic Oncology and selected for an oral presentation at the 2025 ASCO Annual Meeting, one of oncology’s most competitive scientific forums. Now the company has moved into Phase 3. The OVATION-3 trial is a 500-patient, randomized registrational study with overall survival as the primary endpoint. In June 2026, the independent Data Monitoring Committee completed a planned interim safety and efficacy review and recommended the trial continue without modification. That is a significant clinical checkpoint, confirming the trial is proceeding as designed and that no safety signals have emerged to warrant concern. More recently, on July 23rd, 2026, IMUNON presented new IMNN-001 data at the inaugural AACR Conference on Drug Discovery and Development in Boston. Company CEO Stacy Lindborg described the selection as "an important recognition of IMUNON's platform," while Chief Medical Officer Douglas Faller, M.D., Ph.D., stated the program "establishes a new paradigm for immunotherapy" in this setting. A Deeper Company Dive: Imunon, Inc. (Nasdaq: IMNN) Imunon was built from the former clinical-stage company Celsion Corporation, which rebranded in 2022 to reflect its concentrated focus on DNA-based immunotherapy. At the heart of that focus is the proprietary TheraPlas® platform, a non-viral, nanoparticle delivery system designed to transport therapeutic DNA directly into the tumor microenvironment without the manufacturing challenges or immunogenic risks tied to viral vector approaches. IMNN-001 is a DNA plasmid encoding interleukin-12 (IL-12), a potent immune-activating cytokine, delivered intraperitoneally (directly into the abdominal cavity). Earlier attempts to harness IL-12 systemically failed because the doses needed for therapeutic effect caused severe toxicity. Imunon’s approach sidesteps that entirely. By delivering IL-12 locally through TheraPlas®, the company’s treatment activates the immune system at the tumor site, converting an immunologically “cold” tumor into an active, immune-engaged environment, while keeping systemic exposure to a minimum. In OVATION 2, zero serious immune-related adverse events were observed. The pipeline extends well beyond ovarian cancer. The same TheraPlas® platform is being positioned for colorectal cancer, pancreatic cancer, and glioblastoma. IMNN-001 holds FDA Fast Track designation and Orphan Drug designation in both the United States and the European Union, a regulatory package that may support an accelerated path toward a potential BLA submission. The Company's Product Pipeline 7 Key Potential Catalysts Putting (Nasdaq: IMNN) On Our Radar Thursday #1. Phase 3 OVATION-3 Enrollment Is Running Ahead Of Schedule: Enrollment is tracking ahead of plan, with the company reporting it remains on track to enroll approximately 80 patients by the end of Q1 2027. #2. A Named Speaker List From Two Major Cancer Centers: On September 23rd in New York, physicians from MD Anderson and Washington University are scheduled to present translational and efficacy work tied to the lead candidate at IMNN. #3. FDA Alignment On Protocol Removes Key Regulatory Uncertainty: IMUNON has reported FDA alignment on the OVATION 3 protocol design. The company has stated that, if successful, the trial is intended to provide the basis for a BLA filing. This is a critical regulatory milestone that meaningfully reduces uncertainty around the approval process. #4. An Analyst $25 Target Points To Potential Quadruple-Digit Upside: An analyst at Zacks Small Cap Research has pegged a $25 target on IMNN. From Wednesday's close, that target hints at a potential 1,500+% upside. #5. Concentrated Float Could Amplify The Potential For Heightened Volatility: With an estimated public float of approximately 5.29Mn shares, the potential for heightened volatility may be significant on a daily basis. #6. A Pivotal Study Running Ahead Of Its Own Plan: Management reported on July 30th that enrollment in OVATION 3 is exceeding planning assumptions, and IMNN has said two interim analyses are pre-planned. #7. Two Planned Interim Analyses Create Near-Term Data Windows: OVATION-3 includes two pre-planned interim analyses for potential early stopping and BLA submission, meaning IMNN doesn't necessarily need to wait until full trial completion for the first major data readout that could validate the program. Final Thoughts IMUNON, Inc. (Nasdaq: IMNN) is a clinical-stage name carrying a development thesis that is difficult to overlook. Thirty years without a meaningful advance in frontline ovarian cancer treatment is the kind of gap that defines entire careers in the medical space when someone finally closes it. The Phase 2 data is public, peer-reviewed, and published. The Phase 3 trial is actively enrolling, tracking ahead of schedule, and backed by FDA alignment. The DMC just cleared it in June. The company presented at AACR in July. Now, the company will be sharing key progress across their IMNN-001 clinical program later this month at the company's upcoming R&D Day. Register for the webcast here. The body of evidence is building, the scientific community is paying attention, and the potential catalysts ahead are real and time-bound. Coverage is officially underway on IMUNON, Inc. (Nasdaq: IMNN). Stay tuned for updates coming out shortly. Talk again soon. Sincerely, Kai Parker StockWireNews More Sources: IMNN Website IMNN Presentation (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/09/2026 and ending on 09/10/2026 to publicly disseminate information about (IMNN:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the forty two thousand five hundred USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (IMNN:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/imnn-dsxkb/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice